Treatment algorithms for multiple myeloma in Japan

Area of Science:

• Hematology
• Oncology
• Pharmacology

Background:

• Multiple myeloma (MM) treatment has advanced significantly with novel therapeutic agents.
• Several drug classes, including proteasome inhibitors, immunomodulatory drugs (IMiDs), HDAC inhibitors, and monoclonal antibodies, are now available.
• While many agents are approved in Japan, only bortezomib and lenalidomide are approved for initial MM therapy.

Purpose of the Study:

• To summarize recent advancements in multiple myeloma (MM) therapeutics.
• To present the updated Japanese Society of Hematology treatment guidelines for MM.
• To highlight the evolving treatment landscape and the importance of personalized MM treatment strategies.

Main Methods:

• Review of recent therapeutic agent approvals for multiple myeloma (MM) in Japan.
• Analysis of the updated Japanese Society of Hematology treatment guidelines.
• Synthesis of current treatment paradigms for initial, relapsed, and refractory MM.

Main Results:

• Novel agents like proteasome inhibitors, IMiDs, HDAC inhibitors, and monoclonal antibodies have improved MM outcomes.
• Updated guidelines recommend bortezomib-based regimens or lenalidomide+dexamethasone for transplant-eligible patients.
• Bortezomib+melphalan+prednisolone or lenalidomide+dexamethasone are recommended for transplant-ineligible patients.

Conclusions:

• Novel agents have expanded therapeutic options for multiple myeloma (MM), including relapsed or refractory cases.
• The Japanese Society of Hematology has released updated guidelines reflecting these advancements.
• Optimal treatment selection for each MM patient is crucial given the rapidly evolving treatment landscape.